Liraglutide
- Generic Name
- Liraglutide
- Brand Names
- Saxenda, Victoza, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 204656-20-2
- Unique Ingredient Identifier
- 839I73S42A
- Background
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist. Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining...
- Indication
Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m), or who are overweight (BMI≥27 kg/m) and have at least one weight-related comorbidity. It is also indicated for chronic weight management in pediatric patients ≥12 years ol...
- Associated Conditions
- Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 64
- Registration Number
- NCT06546384
- Locations
- 🇨🇭
University Hospital Bern, Bern, Switzerland
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 120
- Registration Number
- NCT06533527
- Locations
- 🇺🇸
Cleveland Clinic, Weston, Florida, United States
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease
- Conditions
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Affiliated Hospital of Nantong University
- Target Recruit Count
- 102
- Registration Number
- NCT06501326
- Locations
- 🇨🇳
Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
LIROH - Liraglutide for Obesity in HIV
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06438146
- Locations
- 🇿🇦
Africa Health Research Institute Clinical Trials Unit, Mtubatuba, South Africa
Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan.
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 288
- Registration Number
- NCT06283641
- Locations
- 🇨🇳
Changhua Christian Hospital, Changhua City, Taiwan
🇨🇳HsinChu Municipal MacKay Children's Hospital, Hsinchu City, Taiwan
🇨🇳HsinChu MacKay Memorial Hospital, Hsinchu City, Taiwan
Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 239990
- Registration Number
- NCT06099067
- Locations
- 🇸🇪
Research Site, Gothenburg, Sweden
Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Beni-Suef University
- Target Recruit Count
- 120
- Registration Number
- NCT05965908
- Locations
- 🇪🇬
Beni-suef university Hospital, Banī Suwayf, Beni Suef, Egypt
Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT05779644
- Locations
- 🇨🇳
Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Anti-obesity Pharmacotherapy and Inflammation
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2024-05-23
- Target Recruit Count
- 24
- Registration Number
- NCT05756764
- Locations
- 🇺🇸
Ochsner Health System - Biospecimen, New Orleans, Louisiana, United States
🇺🇸LSU Clinical & Translational Research Center (CTRC - - LSUHSC-NO, New Orleans, Louisiana, United States
Effects of GH and Lirglutide on AgRP
- Conditions
- Interventions
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 40
- Registration Number
- NCT05681299
- Locations
- 🇺🇸
Neuroendocrine Unit and Pituitary Center, Columbia University Irving Medical Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.